CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $5.77.

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th.

CytomX Therapeutics Stock Up 0.7 %

CytomX Therapeutics stock opened at $1.00 on Thursday. The stock has a 50-day moving average price of $1.14 and a 200 day moving average price of $1.48. The company has a market capitalization of $78.12 million, a price-to-earnings ratio of 7.14 and a beta of 1.06. CytomX Therapeutics has a 52 week low of $0.98 and a 52 week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.01). CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. The business had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. During the same period last year, the company earned ($0.02) earnings per share. Research analysts anticipate that CytomX Therapeutics will post -0.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC acquired a new stake in shares of CytomX Therapeutics in the first quarter valued at about $57,000. Susquehanna Fundamental Investments LLC acquired a new stake in CytomX Therapeutics in the 1st quarter worth about $124,000. Acadian Asset Management LLC increased its stake in CytomX Therapeutics by 1.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,690,830 shares of the biotechnology company’s stock worth $5,863,000 after buying an additional 44,640 shares in the last quarter. Congress Park Capital LLC raised its holdings in shares of CytomX Therapeutics by 393.3% during the second quarter. Congress Park Capital LLC now owns 1,153,220 shares of the biotechnology company’s stock valued at $1,407,000 after acquiring an additional 919,420 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its position in shares of CytomX Therapeutics by 206.0% in the second quarter. Assenagon Asset Management S.A. now owns 1,238,499 shares of the biotechnology company’s stock valued at $1,511,000 after acquiring an additional 833,825 shares in the last quarter. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.